Table 1 Demographic and clinicopathologic findings
From: Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment
All patients, n = 75 | Tumor budding | p | |||
|---|---|---|---|---|---|
Low-intermediate, n = 29 | High, n = 46 | ||||
Gender, N (%) | Female | 24 (32) | 9 (31) | 15 (32) | 0.8 |
Male | 51 (68) | 20 (69) | 31 (68) | ||
Tumor localization, N (%) | Proximal | 13 (17) | 7 (24) | 6 (13) | 0.4 |
Middle | 32 (43) | 11 (38) | 21 (46) | ||
Distal | 30 (40) | 11 (38) | 19 (41) | ||
Pathology, N (%) | Adenocarcinoma | 70 (94) | 26 (90) | 44 (96) | 0.3 |
Mucinous adenocarcinoma | 5 (6) | 3 (10) | 2 (4) | ||
Neoadjuvant chemotherapy, N (%) | 5-Flouracil | 30 (40) | 11 (38) | 19 (41) | 0.5 |
Capecitabine | 45 (60) | 18 (62) | 27 (69) | ||
Surgery, N (%) | Anterior | 4 (5) | 2 (6) | 2 (4) | 0.5 |
Low anterior | 40 (55) | 17 (63) | 23 (52) | ||
Very low anterior | 7 (10) | 1 (3) | 6 (13) | ||
Miles | 23 (30) | 9 (28) | 14 (29) | ||
Total colectomy | 1 (1) | 0 | 1 (2) | ||
Total lymph node excision (median) (min–max) | 18 (5–32) | 19 (5–27) | 17 (5–32) | 0.3 | |
Pathology stage, N (%) | 1 | 14 (19) | 7 (24) | 7 (15) | 0.5 |
2 | 25 (33) | 10 (34) | 15 (33) | ||
3 | 36 (48) | 12 (42) | 24 (52) | ||
Tumor regression | Moderate response | 14 (19) | 7 (24) | 7 (15) | 0.4 |
Minimal response | 23 (30) | 10 (34) | 13 (28) | ||
Poor response | 38 (51) | 12 (42) | 26 (57) | ||
Grade, N (%) | Well | 45 (60) | 18 (62) | 27 (59) | 0.9 |
İntermediate | 10 (13) | 3 (10) | 7 (15) | ||
Poorly | 20 (27) | 8 (28) | 12 (26) | ||
Microsatellite instability status, N (%) | Low | 48 (64) | 23 (79) | 25 (54) | 0.02 |
High | 27 (36) | 6 (21) | 21 (46) | ||